研究目的
To design an upconversion luminance fueled DNA-Azo nanopump for rapid and efficient drug release in cancer therapy.
研究成果
The DNA-Azo nanopump demonstrates efficient and controllable drug release under NIR irradiation, leading to enhanced anticancer therapy. The system shows good biocompatibility and excellent performance in both cellular and in vivo therapy, suggesting its potential for clinical applications in chemotherapy.
研究不足
The study does not address the potential long-term toxicity of the nanopump or its components. The efficiency of the nanopump in other types of cancer cells or in vivo models beyond HepG2 xenograft tumors is not explored.
1：Experimental Design and Method Selection:
The nanopump was constructed by assembling Azo-functionalized DNA strands on upconversion nanoparticles (UCNPs). The selective intercalation of doxorubicin (DOX) in specific DNA helix was used for efficient loading.
2：Sample Selection and Data Sources:
HepG2 cells were used to evaluate the therapeutic efficiency.
3：List of Experimental Equipment and Materials:
NaYF4:Tm,Yb core UCNPs, poly(acrylic acid) modified UCNPs, Azo-functionalized DNA strands, doxorubicin (DOX), HIV-1 TAT peptide, hyaluronic acid (HA).
4：Experimental Procedures and Operational Workflow:
The UCNPs were synthesized and modified with poly(acrylic acid). Azo-functionalized DNA strands were assembled on UCNPs. DOX was loaded onto the DNA helix. The system was tested for drug release under NIR irradiation and evaluated for therapeutic efficiency in vitro and in vivo.
5：Data Analysis Methods:
The release efficiency of DOX was measured using fluorescence spectroscopy. Therapeutic efficiency was evaluated using MTT assay and flow cytometric assay.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
